Prevention and treatment of leucopenia in oncological patients treated with Inmunomodulators Authors Francesco Matozza MD*, Guillermo H. Artero PH**, Guillermo E. Artero MD***, Mónica Rodriguez Laborda MD****, Introduction Purpose of this research was to evaluate changes in quality of life, as well as, number of white blood cells count after administration of immunomodulator treatment, before and during Radiotherapy or chemotherapy. Material and methods A multicentric study included 98 patients with different types of tumors (prostate, breast, uterus, NHL, HL, myeloma, larynx, ovarian, colorectal, stomach, bladder, kidney, lung, pancreas, melanomas). First group included 40 patients, who received immunomodulator treatment prior to chemotherapy or radiotherapy. Second group included 58 patients who presented leucopenia during chemotherapy or radioth erapy, and then were treated with immunomodulator for at least six month.

1° GROUP40 PATIENTSIMMUNO

MODULATOR BEFORE  CT AND RT

2° GROUP58 PATIENTS

WITH LEUCOPENIA

0%

98 PATIENTS WITH DIFFERENT TYPES  OF  TUMOURS

This immunomodulator compound is compose of astragalus, selenium , Zinc, and Mg was administered at least for six month. White blood cell count was measured prior, during and after the treatment Quality of life: Karnovsky, ECOG and chemotherapy treatment recuperation scales were used to evaluate quality of life. Doses: First group received immunomodulator as preventive treatment 4 ml/day. Second group received immunomodulator as treatment 6 ml/day. Results In first group (prior to RT or Chemotherapy) 38 patients, 95% did not present leucopenia during or after treatment. Two patients (5%) had leucopenia during chemotherapy and improved after one month of treatment.

In second group included 58 patients during Chemotherapy and RT. 51 patients (88%) showed an increase of leukocytes count within a month of treatment with immunomodulator and improved their quality of life. 4 patients under chemotherapy did not respond to the treatment with immunomodulators and 3 patient withdrawn the treatment.

Conclusions 95% of Patients with normal WBC treated with immunomodulators prior and during Chemotherapy or Radiotherapy didn’t showed leucopoenia (group 1). 88% of Patients under chemotherapy with leucopoenia, treated with immunomodulator recover the WBC within one month of treatment (group 2). Immunomodulator treatment improve quality of life in cancer patients, measured by Karnofsky, and ECOG scales, administered prior to CT or RT prevent leucopoenia. It could be used in patient under Chemotherapy or radiotherapy treatment in order to avoid leucopoenia and treatment delay. Bibliografía 1-Zhu XL, Zhu BD. 1-Mechanisms by which Astragalus membranaceus injection regulates hematopoiesis in myelosuppressed mice.Phytother Res. 2007 Jul;21(7):663-7. PMID: 17421056 [PubMed - indexed for MEDLINE] 2-Tin MM, Cho CH, Chan K, James AE, Ko JK. Astragalus saponins induce growth inhibition and apoptosis in human colon cancer cells and tumor xenograft. Carcinogenesis. 2007 Jun;28(6):1347-55. Epub 2006 Dec 5. PMID: 17148504 [PubMed - indexed for MEDLINE] 3-McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, Gao J, Lieb W, Shieh K, Colford JM Jr.

Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol. 2006 Jan 20;24(3):419-30. PMID: 16421421 [PubMed - indexed for MEDLINE] 4-Block KI, Mead MN. Immune system effects of echinacea, ginseng, and astragalus: a review. Integr Cancer Ther. 2003 Sep;2(3):247-67. Review. PMID: 15035888 [PubMed - indexed for MEDLINE] 5-Chen L, Xie C, Wu L. Point injection of injectio radici astragali for treatment of post-chemotherapy adverse reactions. J Tradit Chin Med. 2005 Mar;25(1):21-2. No abstract available. PMID: 15889516 [PubMed - indexed for MEDLINE] 6-Chu DT, Wong WL, Mavligit GM. Immunotherapy with Chinese medicinal herbs. II. Reversal of cyclophosphamide-induced immune suppression by administration of fractionated Astragalus membranaceus in vivo. J Clin Lab Immunol. 1988 Mar;25(3):125-9. PMID: 3260961 [PubMed - indexed for MEDLINE] 7-Sun Y, Hersh EM, Lee SL, McLaughlin M, Loo TL, Mavligit GM. Preliminary observations on the effects of the Chinese medicinal herbs Astragalus membranaceus and Ligustrum lucidum on lymphocyte blastogenic responses. J Biol Response Mod. 1983;2(3):227-37. PMID: 6644339 [PubMed - indexed for MEDLINE] 8-Chen L, Xie C, Wu L. Point injection of injectio radici astragali for treatment of post-chemotherapy adverse reactions. J Tradit Chin Med. 2005 Mar;25(1):21-2. No abstract available. PMID: 15889516 [PubMed - indexed for MEDLINE] 9-Zareifar S, Sharifian M. Zinc supplement may be effective in febrile neutropenia. Indian J Pediatr. 2007 Oct;74(10):964-5. No abstract available. PMID: 17978463 [PubMed - indexed for MEDLINE] 10--Fraker PJ, Jardieu P, Cook J. Zinc deficiency and immune function. Arch Dermatol. 1987 Dec;123(12):1699-701. Review. PMID: 3120653 [PubMed - indexed for MEDLINE] 11--Fraker PJ. Zinc deficiency: a common immunodeficiency state. Surv Immunol Res. 1983;2(2):155-63. Review. No abstract available. PMID: 6359328 [PubMed - indexed for MEDLINE] Francesco Matozza Is Oncologist at Rawson Hospital in Buenos Aires, Guillermo E. Artero is physician at Tornu Hospital in Buenos Aires Guillermo H Artero is pharmacist in pharmaceutical industry in Buenos Aires.,Argentina Monica Rodriguez Laborda is psychoimmunoendocrinologist in prívate clinic Buenos Aires

Contact F.Matozza M:D. frankmatozza@libero.it G.H.Artero Ph arteroguillermo@fibertel.com.ar